Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' p... Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. Show more
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare...
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.01 | -5.87719298246 | 34.2 | 34.64 | 31.57 | 680182 | 32.82139292 | CS |
4 | -27.18 | -45.7806973219 | 59.37 | 62.45 | 31.57 | 1241926 | 40.52964818 | CS |
12 | -9.44 | -22.6759548403 | 41.63 | 62.58 | 31.57 | 804190 | 46.59196085 | CS |
26 | -10.17 | -24.0084985836 | 42.36 | 62.58 | 31.57 | 635335 | 45.99636253 | CS |
52 | 8.61 | 36.5139949109 | 23.58 | 62.58 | 20.96 | 729560 | 38.288393 | CS |
156 | -0.84 | -2.54314259764 | 33.03 | 62.58 | 16.75 | 615401 | 30.82638448 | CS |
260 | -14.67 | -31.3060179257 | 46.86 | 62.58 | 16.75 | 642921 | 37.26774324 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales